查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179529

銀屑病治療藥物市場:按藥物類別、類型和給藥途徑分類:全球機會分析和行業預測，2021-2031 年

Psoriasis Therapeutics Market By Drug Class, By Type, By Route of Administration : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 242 Pages | 商品交期: 2-3個工作天內

價格

牛皮癬是一種皮膚病，會導致皮膚細胞的生長速度比正常情況快 10 倍。

這會導致皮膚變成覆蓋著白色鱗屑的凹凸不平的紅色斑塊。 它們可以出現在任何地方，但最常見於頭皮、肘部、膝蓋和下背部。 牛皮癬不會在人與人之間傳播。 但有時它發生在同一個家庭中。 牛皮癬通常發生在成年早期。 大多數人只會在幾個地方出現症狀。 在嚴重的情況下，它可能會覆蓋大部分身體。 牛皮癬可以終生治愈或複發。 然而，有許多治療方法。 有些可以減緩新皮膚細胞的生長，而另一些則可以舒緩瘙癢和乾燥的皮膚。 您的醫生會根據皮疹的大小、皮疹在身體上的位置、年齡、一般狀況和患者的其他情況，為您的患者選擇正確的治療方案。 常見的治療方法包括類固醇乳膏、乾性皮膚保濕劑煤焦油（一種治療頭皮牛皮癬的常見藥物，有乳液、乳霜、泡沫、洗髮水和沐浴液）、維生素 D 基乳膏和軟膏，以及維甲酸乳膏等。

推動全球銀屑病治療市場增長的主要因素是老年人口的增長、斑塊和銀屑病關節炎患病率的增加、優惠的報銷政策以及生物製劑處方量的增加。例如 此外，人們對市場上可用的各種治療方法的認識不斷提高，進一步推動了市場的增長。 然而，在預測期內，與治療成本上升相關的藥物引起的健康風險正在抑制銀屑病治療市場的增長。 相反，新生物製劑和新管道藥物的開發不斷增加，未開發的新興國家的高增長潛力有望為市場參與者提供有利可圖的機會。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • COVID-19 影響分析
  • 專利情況

第 4 章銀屑病藥物市場:按治療類別分類

  • 概覽
    • 市場規模和預測
  • TNF-ALPHA 抑製劑
    • 主要市場趨勢、增長因素和機遇
    • 各地區的市場規模和預測
    • 市場分析:按國家/地區分類
  • 白細胞介素抑製劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區分類
    • 白細胞介素抑製劑銀屑病藥物市場:按分銷渠道
      • 醫院藥房市場規模和預測:按地區
      • 藥店和零售藥店市場規模和預測:按地區
      • 在線提供商市場規模趨勢和預測:按地區
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區分類

第 5 章銀屑病藥物市場:按類型

  • 概覽
    • 市場規模和預測
  • 斑塊狀銀屑病
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區分類
  • 銀屑病關節炎
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區分類

第 6 章銀屑病藥物市場:按給藥途徑

  • 概覽
    • 市場規模和預測
  • 口語
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區分類
  • 父母代理人
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區分類
  • 外部代理
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區分類

第 7 章銀屑病藥物市場:按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機會
    • 北美市場規模和預測:按藥物類別
      • 按白細胞介素抑製劑劃分的北美銀屑病藥物市場:按分銷渠道
    • 北美市場規模和預測:按類型
    • 北美市場規模和預測:按給藥途徑
    • 北美市場規模和預測:按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機會
    • 歐洲市場規模和預測:按藥物類別
      • 按白細胞介素抑製劑劃分的歐洲銀屑病藥物市場:按分銷渠道
    • 歐洲市場規模和預測:按類型
    • 歐洲市場規模和預測:按給藥途徑
    • 歐洲市場規模和預測:按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲
  • 亞太地區
    • 主要趨勢和機會
    • 按藥物類別劃分的亞太市場規模和預測
      • 按白介素抑製劑劃分的亞太地區銀屑病藥物市場:按分銷渠道
    • 亞太市場規模和預測:按類型
    • 按給藥途徑劃分的亞太地區市場規模和預測
    • 亞太地區的市場規模和預測:按國家/地區分類
      • 日本
      • 中國
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機會
    • LAMEA 銀屑病藥物市場規模和預測:按藥物類別
      • 白細胞介素抑製劑的 LAMEA 銀屑病藥物市場:按分銷渠道
    • LAMEA 市場規模和預測:按類型
    • LAMEA 市場規模和預測:按給藥途徑
    • LAMEA 市場規模和預測:按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其餘部分

第八章公司情況

  • 介紹
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第九章公司簡介

  • Abbvie Inc.
  • Amgen Inc.
  • Bausch Health Companies Inc.
  • Eli Lilly and Company
  • Johnson and Johnson
  • LEO Pharma
  • Novan Inc.（EPI Health LLC）
  • Novartis AG
  • Pfizer Inc.
  • Viatris Inc.（Mylan NV）
Product Code: A03405

Psoriasis is a skin disorder that causes skin cells to multiply up to 10 times faster than normal. This makes the skin build up into bumpy red patches covered with white scales. They can grow anywhere, but most appear on scalp, elbows, knees, and lower back. Psoriasis cannot pass from person to person. It does sometimes happen in members of the same family. Psoriasis usually appears in early adulthood. For most people, it affects just a few areas. In severe cases, it can cover large parts of the body. The patches can heal and then come back throughout a person's life. However, there are many treatments. Some slow the growth of new skin cells, and others relieve itching and dry skin. Doctor selects a treatment plan that is right for patient based on the size of rash, where it is on the body, age, overall health, and other things of patients. Common treatments include steroid creams, moisturizers for dry skin coal tar (a common treatment for scalp psoriasis available in lotions, creams, foams, shampoos, and bath solutions), vitamin D-based cream or ointments, and Retinoid creams.

Major factors that drive growth of the global psoriasis therapeutics market include increase in geriatric population, growth in prevalence of plaque and psoriatic arthritis, favorable reimbursement policies, and rise in prescription volume of biological products. In addition, rise in awareness among people regarding different treatments available in the market further propel the market growth. However, health risks posed, owing to medication along with high costs of therapies restrain growth of the psoriasis therapeutics market during the forecast period. Conversely, increase in development of new biologics and novel pipeline drugs and high growth potential in untapped emerging countries are anticipated to provide lucrative opportunities to the market players.

The psoriasis therapeutics market is segmented on the basis of drug class, type, route of administration, end user, and region. According to drug class, the market is categorized into TNF-alpha inhibitors, interleukin inhibitors, and others. Interleukin inhibitors further segmented by distribution channel, including hospital pharmacies, drug stores & retail pharmacies, and online providers. On the basis of type, it is divided into plaque psoriasis, psoriatic arthritis, and others. On the basis of route of administration, it is classified into oral, topical, and parenteral. Furthermore, regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include: AbbVie Inc., Amgen Inc., Bausch Health Companies Inc, Eli Lilly and Company, Johnson & Johnson (J&J), Leo Pharma A/S, Novan, Inc., Novartis AG, Pfizer Inc., and Viatris Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the psoriasis therapeutics market analysis from 2021 to 2031 to identify the prevailing psoriasis therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the psoriasis therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global psoriasis therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

  • TNF-alpha Inhibitors
  • Interleukin Inhibitors
    • Distribution Channel
    • Hospital Pharmacies
    • Drug Stores and Retail Pharmacies
    • Online Providers
  • Others

By Type

  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Rest Of Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Abbvie Inc.
    • Amgen Inc.
    • Bausch Health Companies Inc.
    • Eli Lilly and Company
    • Johnson and Johnson
    • LEO Pharma
    • Novan Inc. (EPI Health LLC)
    • Novartis AG
    • Pfizer Inc.
    • Viatris Inc. (Mylan NV)

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Patent Landscape

CHAPTER 4: PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 TNF-alpha Inhibitors
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Interleukin Inhibitors
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
    • 4.3.4 Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
      • 4.3.4.1 Hospital Pharmacies Market size and forecast, by region
      • 4.3.4.2 Drug Stores and Retail Pharmacies Market size and forecast, by region
      • 4.3.4.3 Online Providers Market size and forecast, by region
  • 4.4 Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: PSORIASIS THERAPEUTICS MARKET, BY TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Plaque Psoriasis
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Psoriatic Arthritis
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Others
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Oral
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Parenteral
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Topical
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: PSORIASIS THERAPEUTICS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Drug Class
      • 7.2.2.1 North America Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
    • 7.2.3 North America Market size and forecast, by Type
    • 7.2.4 North America Market size and forecast, by Route of Administration
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Drug Class
      • 7.2.5.1.2 Market size and forecast, by Type
      • 7.2.5.1.3 Market size and forecast, by Route of Administration
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Drug Class
      • 7.2.5.2.2 Market size and forecast, by Type
      • 7.2.5.2.3 Market size and forecast, by Route of Administration
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Drug Class
      • 7.2.5.3.2 Market size and forecast, by Type
      • 7.2.5.3.3 Market size and forecast, by Route of Administration
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Drug Class
      • 7.3.2.1 Europe Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
    • 7.3.3 Europe Market size and forecast, by Type
    • 7.3.4 Europe Market size and forecast, by Route of Administration
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Drug Class
      • 7.3.5.1.2 Market size and forecast, by Type
      • 7.3.5.1.3 Market size and forecast, by Route of Administration
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Drug Class
      • 7.3.5.2.2 Market size and forecast, by Type
      • 7.3.5.2.3 Market size and forecast, by Route of Administration
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Drug Class
      • 7.3.5.3.2 Market size and forecast, by Type
      • 7.3.5.3.3 Market size and forecast, by Route of Administration
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Drug Class
      • 7.3.5.4.2 Market size and forecast, by Type
      • 7.3.5.4.3 Market size and forecast, by Route of Administration
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Drug Class
      • 7.3.5.5.2 Market size and forecast, by Type
      • 7.3.5.5.3 Market size and forecast, by Route of Administration
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Drug Class
      • 7.3.5.6.2 Market size and forecast, by Type
      • 7.3.5.6.3 Market size and forecast, by Route of Administration
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
      • 7.4.2.1 Asia-Pacific Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
    • 7.4.3 Asia-Pacific Market size and forecast, by Type
    • 7.4.4 Asia-Pacific Market size and forecast, by Route of Administration
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Drug Class
      • 7.4.5.1.2 Market size and forecast, by Type
      • 7.4.5.1.3 Market size and forecast, by Route of Administration
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Drug Class
      • 7.4.5.2.2 Market size and forecast, by Type
      • 7.4.5.2.3 Market size and forecast, by Route of Administration
      • 7.4.5.3 India
      • 7.4.5.3.1 Market size and forecast, by Drug Class
      • 7.4.5.3.2 Market size and forecast, by Type
      • 7.4.5.3.3 Market size and forecast, by Route of Administration
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Market size and forecast, by Drug Class
      • 7.4.5.4.2 Market size and forecast, by Type
      • 7.4.5.4.3 Market size and forecast, by Route of Administration
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Drug Class
      • 7.4.5.5.2 Market size and forecast, by Type
      • 7.4.5.5.3 Market size and forecast, by Route of Administration
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Drug Class
      • 7.4.5.6.2 Market size and forecast, by Type
      • 7.4.5.6.3 Market size and forecast, by Route of Administration
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Drug Class
      • 7.5.2.1 LAMEA Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
    • 7.5.3 LAMEA Market size and forecast, by Type
    • 7.5.4 LAMEA Market size and forecast, by Route of Administration
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Drug Class
      • 7.5.5.1.2 Market size and forecast, by Type
      • 7.5.5.1.3 Market size and forecast, by Route of Administration
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Drug Class
      • 7.5.5.2.2 Market size and forecast, by Type
      • 7.5.5.2.3 Market size and forecast, by Route of Administration
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Drug Class
      • 7.5.5.3.2 Market size and forecast, by Type
      • 7.5.5.3.3 Market size and forecast, by Route of Administration
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Drug Class
      • 7.5.5.4.2 Market size and forecast, by Type
      • 7.5.5.4.3 Market size and forecast, by Route of Administration

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Abbvie Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Amgen Inc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Bausch Health Companies Inc.
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Eli Lilly and Company
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Johnson and Johnson
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 LEO Pharma
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Novan Inc. (EPI Health LLC)
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Novartis AG
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Pfizer Inc.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Viatris Inc. (Mylan NV)
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 2. PSORIASIS THERAPEUTICS MARKET, FOR TNF-ALPHA INHIBITORS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. PSORIASIS THERAPEUTICS MARKET FOR TNF-ALPHA INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. PSORIASIS THERAPEUTICS MARKET, FOR INTERLEUKIN INHIBITORS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. PSORIASIS THERAPEUTICS MARKET FOR INTERLEUKIN INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. GLOBAL INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 7. PSORIASIS THERAPEUTICS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 8. PSORIASIS THERAPEUTICS MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. PSORIASIS THERAPEUTICS MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. PSORIASIS THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. PSORIASIS THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 13. PSORIASIS THERAPEUTICS MARKET, FOR PLAQUE PSORIASIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. PSORIASIS THERAPEUTICS MARKET FOR PLAQUE PSORIASIS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 15. PSORIASIS THERAPEUTICS MARKET, FOR PSORIATIC ARTHRITIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. PSORIASIS THERAPEUTICS MARKET FOR PSORIATIC ARTHRITIS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. PSORIASIS THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. PSORIASIS THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 19. GLOBAL PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 20. PSORIASIS THERAPEUTICS MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 21. PSORIASIS THERAPEUTICS MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 22. PSORIASIS THERAPEUTICS MARKET, FOR PARENTERAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. PSORIASIS THERAPEUTICS MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 24. PSORIASIS THERAPEUTICS MARKET, FOR TOPICAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. PSORIASIS THERAPEUTICS MARKET FOR TOPICAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 26. PSORIASIS THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 30. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 31. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 32. U.S. PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 33. U.S. PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 34. U.S. PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 35. CANADA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 36. CANADA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 37. CANADA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 38. MEXICO PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 39. MEXICO PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 40. MEXICO PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 41. EUROPE PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 42. EUROPE INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 43. EUROPE PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 44. EUROPE PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 45. EUROPE PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 46. GERMANY PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 47. GERMANY PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 48. GERMANY PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 49. FRANCE PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 50. FRANCE PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 51. FRANCE PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 52. UK PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 53. UK PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 54. UK PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 55. ITALY PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 56. ITALY PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 57. ITALY PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 58. SPAIN PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 59. SPAIN PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 60. SPAIN PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 61. REST OF EUROPE PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 62. REST OF EUROPE PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 63. REST OF EUROPE PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 64. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 65. ASIA-PACIFIC INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 66. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 67. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 68. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 69. JAPAN PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 70. JAPAN PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 71. JAPAN PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 72. CHINA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 73. CHINA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 74. CHINA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 75. INDIA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 76. INDIA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 77. INDIA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 78. AUSTRALIA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 79. AUSTRALIA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 80. AUSTRALIA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 83. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 84. REST OF ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 85. REST OF ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 86. REST OF ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 87. LAMEA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 88. LAMEA INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 89. LAMEA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 90. LAMEA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 91. LAMEA PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 92. BRAZIL PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 93. BRAZIL PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 94. BRAZIL PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 95. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 96. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 97. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 98. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 99. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 100. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 101. REST OF LAMEA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 102. REST OF LAMEA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 103. REST OF LAMEA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 104.ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 105.ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 106.ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 107.ABBVIE INC.: NET SALES,
  • TABLE 108.ABBVIE INC.: KEY STRATERGIES
  • TABLE 109.AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 110.AMGEN INC.: OPERATING SEGMENTS
  • TABLE 111.AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 112.AMGEN INC.: NET SALES,
  • TABLE 113.AMGEN INC.: KEY STRATERGIES
  • TABLE 114.BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
  • TABLE 115.BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS
  • TABLE 116.BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
  • TABLE 117.BAUSCH HEALTH COMPANIES INC.: NET SALES,
  • TABLE 118.BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES
  • TABLE 119.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 120.ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 121.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 122.ELI LILLY AND COMPANY: NET SALES,
  • TABLE 123.ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 124.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 125.JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 126.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 127.JOHNSON AND JOHNSON: NET SALES,
  • TABLE 128.JOHNSON AND JOHNSON: KEY STRATERGIES
  • TABLE 129.LEO PHARMA: COMPANY SNAPSHOT
  • TABLE 130.LEO PHARMA: OPERATING SEGMENTS
  • TABLE 131.LEO PHARMA: PRODUCT PORTFOLIO
  • TABLE 132.LEO PHARMA: NET SALES,
  • TABLE 133.LEO PHARMA: KEY STRATERGIES
  • TABLE 134.NOVAN INC. (EPI HEALTH LLC): COMPANY SNAPSHOT
  • TABLE 135.NOVAN INC. (EPI HEALTH LLC): OPERATING SEGMENTS
  • TABLE 136.NOVAN INC. (EPI HEALTH LLC): PRODUCT PORTFOLIO
  • TABLE 137.NOVAN INC. (EPI HEALTH LLC): NET SALES,
  • TABLE 138.NOVAN INC. (EPI HEALTH LLC): KEY STRATERGIES
  • TABLE 139.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 140.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 141.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 142.NOVARTIS AG: NET SALES,
  • TABLE 143.NOVARTIS AG: KEY STRATERGIES
  • TABLE 144.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 145.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 146.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 147.PFIZER INC.: NET SALES,
  • TABLE 148.PFIZER INC.: KEY STRATERGIES
  • TABLE 149.VIATRIS INC. (MYLAN NV): COMPANY SNAPSHOT
  • TABLE 150.VIATRIS INC. (MYLAN NV): OPERATING SEGMENTS
  • TABLE 151.VIATRIS INC. (MYLAN NV): PRODUCT PORTFOLIO
  • TABLE 152.VIATRIS INC. (MYLAN NV): NET SALES,
  • TABLE 153.VIATRIS INC. (MYLAN NV): KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.PSORIASIS THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 2.PSORIASIS THERAPEUTICS MARKET,2021-2031
  • FIGURE 3.PSORIASIS THERAPEUTICS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.PSORIASIS THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.PATENT ANALYSIS BY COMPANY
  • FIGURE 13.PATENT ANALYSIS BY COUNTRY
  • FIGURE 14.PSORIASIS THERAPEUTICS MARKET,BY DRUG CLASS,2021(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF TNF-ALPHA INHIBITORS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 18.PSORIASIS THERAPEUTICS MARKET,BY TYPE,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF PLAQUE PSORIASIS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF PSORIATIC ARTHRITIS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 22.PSORIASIS THERAPEUTICS MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ORAL PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF PARENTERAL PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF TOPICAL PSORIASIS THERAPEUTICS MARKET,2021-2031(%)
  • FIGURE 26.PSORIASIS THERAPEUTICS MARKET BY REGION,2021
  • FIGURE 27.U.S. PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 28.CANADA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 29.MEXICO PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 30.GERMANY PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 31.FRANCE PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 32.UK PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 33.ITALY PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 34.SPAIN PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 35.REST OF EUROPE PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 36.JAPAN PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 37.CHINA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 38.INDIA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 39.AUSTRALIA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 40.SOUTH KOREA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 41.REST OF ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 42.BRAZIL PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 43.SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 44.SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 45.REST OF LAMEA PSORIASIS THERAPEUTICS MARKET,2021-2031($MILLION)
  • FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 50.COMPETITIVE DASHBOARD
  • FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 52.ABBVIE INC..: NET SALES ,($MILLION)
  • FIGURE 53.AMGEN INC..: NET SALES ,($MILLION)
  • FIGURE 54.BAUSCH HEALTH COMPANIES INC..: NET SALES ,($MILLION)
  • FIGURE 55.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
  • FIGURE 56.JOHNSON AND JOHNSON.: NET SALES ,($MILLION)
  • FIGURE 57.LEO PHARMA.: NET SALES ,($MILLION)
  • FIGURE 58.NOVAN INC. (EPI HEALTH LLC).: NET SALES ,($MILLION)
  • FIGURE 59.NOVARTIS AG.: NET SALES ,($MILLION)
  • FIGURE 60.PFIZER INC..: NET SALES ,($MILLION)
  • FIGURE 61.VIATRIS INC. (MYLAN NV).: NET SALES ,($MILLION)